Skip to main content
. 2023 Mar 9;14:1164514. doi: 10.3389/fimmu.2023.1164514

Figure 1.

Figure 1

Numerous HDAC inhibitors suppress histone deacetylases in breast cancer. Dacinostat, belinostat, abexinostat, mocetinotat, panobinostat, romidepsin, entinostat and vorinostat, inhibit histone deacetylases and regulate breast tumorigenesis, progression and immunotherapy.